Masimo yesterday announced that it received FDA 510(k) clearance for a new monitor feature to detect breathing problems in patients receiving opioid therapy.
Masimo designed the new capability, which uses AI-enabled analysis, for its Radius VSM wearable continuous patient monitor.
The clearance marks the first implementation of Masimo’s opioid-induced respiratory depression (OIRD) detection technology in a hospital monitoring solution, according to the company.
It’s the most recent approval for the company since it became a part of Danaher’s diagnostics segment through a $9.9 billion acquisition this month.
Related links:
